1. Home
  2. COVID Rapid Tests
  3. CovClear Rapid COVID-19 Test (Box of 50)
CovClear Rapid COVID-19 Test (Box of 50)
CovClear Rapid COVID-19 Test

CovClear Rapid COVID-19 Test (Box of 50)

Your Price: $900.00
Part Number: ATG900-031
Availability: In Stock.

Required

*
Quantity Price
200 - 999 $800.00
1000+ $700.00
 

The CovClear Rapid Antigen test is a lateral flow immunochromatographic assay for the detection of extracted nucleocapsid protein antigens specific to SARS-CoV-2 in nasopharyngeal swab specimens directly collected

Simple to useSimple to use - Rapid Results in 3-20 Minutes

No Reader RequiredNo Reader Required – Reduced Cost

Highly Sensitive and SpecificHighly Sensitive and Specific – Outperforming other antigen tests

No Cassette NeededNo Cassette Needed – Reduced Material Wastage

Safety AdvantageSafety Advantage – Sealed Vial Protecting Collector Against Live Virus

Early DetectionEarly Detection – Reduced Exposure

Researched, developed & manufactured in the USAResearched, developed & manufactured in the USA

PERFORMANCE

 

 
97% Sensitivity
98.5%

Sensitive

96.8% Positive
100%

Specific

 

Validated by Empowered Diagnostics, LLC. CovClear has been validated, but the FDA’s independent review of this validation is pending.

Intended Use


The CovClear™ COVID-19 Antigen Test is a lateral flow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly collected. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high complexity tests, and at the Point of Care (POC), i.e., in patient care settings operating under a high complexity CLIA Certificate. Results are for the identification of the SARS-CoV-2 nucleocapsid protein antigen. The antigen is generally detectable in nasal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but the clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out a bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities. Negative results are presumptive and confirmation with a molecular assay, if necessary, for patient management may be performed. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19. The CovClear™ COVID-19 Antigen Test is intended for use by medical professionals or trained operators who are proficient in performing tests and trained clinical laboratory personnel or individuals trained in Point of Care settings. The CovClear™ COVID-19 Antigen Test is only for use under the Food and Drug Administration’s Emergency Use Authorization (EUA).

CovClear Antigen Test

For informational purposes only. Testing is limited to laboratories and patient care settings operating under a high complexity CLIA Certificate.

Sample Collection

CovClear - Step 11

Remove a swab from the pouch.

CovClear - Step 22

Place the dry swab into one of the patient’s nostrils until it reaches resistance.

CovClear - Step 33

Slowly rotate the swab 7 times over the surface inside the nostril.

CovClear - Step 44

Slowly remove the swab from the nostril while still rotating it. Repeat steps 2-4 on other nostril.

Test Instructions

CovClear Instructions: Step 11

Pour entire buffer solution ampule into empty vial.

CovClear Instructions: Step 22

Insert dry swab into one nostril until you meet resistance. Swirl 7 times. Repeat with the same swab in other nostril.

CovClear Instructions: Step 33

Place swab into prepared vial with buffer solution. Slightly swirl the vial and swab for 30 seconds.

NOTE: DO NOT place the cap on the vial. DO NOT remove the swab.

CovClear Instructions: Step 44

Press tip against side of vial to squeeze liquid from swab for 10 seconds. Then place swab back into the buffer solution.

NOTE: DO NOT remove the swab.

CovClear Instructions: Step 55

Place new test strip, arrow pointing down, into vial with the swab.

NOTE: Touch test strip on the colored end only.

CovClear Instructions: Step 66

Place cap securely onto the vial with the test strip and swab inside.

NOTE: Cap will permanently lock in place. DO NOT tip vial over as this will invalidate the test.

READ RESULTS AFTER 3 MINUTES
DO NOT READ RESULTS PAST 20 MINUTES

Interpretation of Results

CovClear Results

Clinical Performance

A total of 76 blinded dry nasal swab samples were tested in one investigational site to evaluate the clinical performance of the CovClear™ SARS-Cov-2 Rapid Antigen Test strip. Nasal swab specimens were collected from patients with COVID-19 like symptoms during the 2020 COVID-19 season. All the Nasal swabs were added to the CovClear™ vial (either dry or in buffer). All the Nasal swab specimens were confirmed as positive or negative and validated with Ct value by the FDA EUA RT-PCR as a comparator method. The samples were randomized, blinded and tested using the instructions provided by the Instruction for Use.

All the study samples were random and assigned a study ID prior to testing. The expected results of the sample were completely blinded to the operators. 11% of the positive samples had Ct values over 30.

CovClear Chart

Analytical Sensitivity: Limit of Detection (LoD)

The LoD for direct swab was established using heat-inactivated SARS-CoV-2 isolate Hong Kong/VM20001061/2020). The strain was spiked into 0.5 saline solution prepared in accordance with BAM R66. The estimated LoD found from the initial two- fold serial dilution test was confirmed by testing 20 replicates. The confirmed LoD for direct swab was 7.12 x 103 TCID50/ml.

Specimen Stability:

The specimen stability was established using heat-inactivated SARS-CoV-2 isolate Hong Kong/VM20001061/2020. The strain was spiked into 0.5% saline solution at 3x the LoD (2.16 x 104 TCID50/ml). Samples were then Incubated at room temperature for 0, 2 6, and 24 hours respectively prior to testing. All samples tested produced no qualitative impact on test line signal intensity as compared to the 0-hour condition, demonstrating that the CovClear™ COVID-19 Antigen Test performance was not affected by sample Instability for up to 24 hours at room temperature.

Analytical Specificity: Cross Reactivity and Microbial Interference

The potential cross-reactivity (exclusivity) of a panel of common organisms was evaluated with SARS-CoV-2 negative samples using the CovClear™ COVID-19 Antigen Test. Potential microbial interference was evaluated with samples containing heat-inactivated SARS-CoV-2 isolate isolate Hong Kong/VM20001061/2020 at approximately 3x LoD. A total of 7 bacteria were tested at a target at approximately 1 x 106 cfu/ml. The 13 viruses were tested at concentrations between 9.87 x 104 and 1 x 105 pfu. All negative samples gave negative results at the concentrations of the potentially cross-reactive common organisms tested showing no cross-reactivity with CovClear™ COVID-19 Antigen assay. All samples with SARS-CoV-2 strain tested positive showing no microbial interference at the concentrations of the potentially interfering common organisms tested.

Cross Reactant

SARS-coronavirus was not tested as part of this study. Additional testing may be required to determine if this pathogen will generate cross-reactivity at the CovClear test line.

To estimate the likelihood of cross-reactivity with SARS-CoV-2 of organisms that were not available for wet testing, in silico analysis using the Basic Local Alignment Search Tool (BLAST) managed by the National Center for Biotechnology Information (NCBI) was used to assess the degree of protein sequence homology.

  • https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins&PROGRAM=blastp&BLAST_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&DATABASE=n/a&QUERY=&SUBJECTS=
  • The homology between SARS-CoV-2 nucleocapsid protein and human coronavirus HKU1 nucleocapsid protein is relatively low, at 36.7% across 86.4% of sequences, but cross- reactivity cannot be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and Mycobacterium tuberculosis total protein (3,991 proteins) is relatively low, homology-based cross-reactivity can be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and Pneumocystis jirovecii total protein (3,745 proteins) is relatively low, homology-based cross-reactivity can be ruled out.
  • The homology between SARS-CoV-2 nucleocapsid protein and human coronavirus 229E nucleocapsid protein is relatively low, but cross- reactivity cannot be ruled out. However, a result of the cross-reactivity wet study showed that CovClear™ COVID-19 Antigen had no cross-reactivity against human coronavirus 229E.
  • No homologous protein was detected as a result of in silico assay with the proteins of Mycoplasma pneumoniae and the nucleocapsid protein (NP) of SARS-CoV-2. So, cross-reactivity of CovClear™ COVID-19 Antigen against Mycoplasma pneumoniae can be ruled out.

Endogenous Interfering Substances Effect

To assess substances with the potential to interfere with the performance of the CovClear™ COVID-19 Antigen Test, positive and negative samples were tested with the addition of potentially interfering substances. The SARS-CoV-2 target concentration in the positive samples was approximately 2x LoD. All samples tested produced no qualitative impact to test line signal intensity, demonstrating that the CovClear™ COVID-19 Antigen Test performance was not affected by any of the 14 potentially interfering substances listed in the table below at the concentrations tested.

Interfering Substances

The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results. Biotin concentrations =2.5 µg/ml can cause false-negative COVID-19 results with the CovClear™ COVID-19 Antigen Test.

High-dose Hook Effect

The CovClear™ COVID-19 Antigen Test was tested up to 1.15 x 105 TCID50/ml of heat-inactivated SARS- CoV-2 strain and no high-dose hook effect was observed.

Technical Support

For questions, or to report a problem, please call Empowered Diagnostics at 954-354-2768.

Test system problems may also be reported to the FDA using the MedWatch reporting system (phone: 1-800-FDA-1088; fax: 1-800-FDA-1078: or http://www.fda.gov/medwatch).

Related Items

15 Minute Covid Rapid Test
COVID-19 Rapid Antigen Tests
$239.00
In Stock and Ships Same or Next Day!
COVID-19 Rapid Antibody Test
covid rapid test
$475.00
Backordered until Week of 9/27. Orders placed will ship first in first out.

Recently Viewed Items